The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, shares thoughts on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Tags: ASH Conference CoverageMultiple Myeloma
Published: 14 December 2018
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...
Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, shares updates from the CLL14 study presented at ASH 2019 and elaborates on the role of debulking plays in the management of chronic lymphocytic leukemia (CLL)
Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, tells us about the four-year update on the outcomes of the MURANO study investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic lymphoma (CLL)
Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the results of the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma (MCL) patients
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019
Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, provides opinion on current treatment strategies for elderly acute myeloid leukemia (AML) patients
Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma
Dr. Yasenchak, Medical Oncologist, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma
Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, outlines the clinical factors associated with improved survival after CD19 CAR-T cell therapy in adult patients with B-cell acute lymphoblastic leukemia
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, explains how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL)
Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, speculates on how the addition of oral HMAs will impact the landscape in myeloid malignancies
Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL)
Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, on the benefits of zanubrutinib as compared to other BTK inhibitors in the management of lymphoma
Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, on the impact of the ECHELON-2 trial data presented at ASH 2019
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.